Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions
The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.
G-CON Manufacturing and Pall Corporation are collaborating to bring turnkey continuous bioprocess or viral vector production facility solutions to the industry. G-CON PODs will be customized with advanced Pall Biotech bioprocess equipment, including automation and utility supplies; these will be predesigned into the G-CON cleanroom units for scalable deployment.
“Together, Pall’s cutting-edge technology and G-CON’s flexible cleanroom platform take the concept of modularity one step further, delivering a complete, reproducible, scalable facility solution that is easy to place or relocate, as well as clean, sanitize and even repurpose,” said Mario Philips, Vice President & General Manager at Pall Biotech. “This strategic collaboration is particularly important to Pall, as we continuously improve bioprocesses for the industry by offering innovative solutions like G-CON PODs customized with Pall technologies. This solution addresses customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing.”
PODs from G-CON are mobile, and include integrated process piping and heating and air conditioning (HVAC) systems. Deploying the customized PODs is simple by design, allowing a customer to focus on the target molecule, while relying on the G-CON and Pall teams to optimize the facility design and process. Once designed, the PODs ease verification, qualification and validation challenges by providing comprehensive site acceptance testing and even IQ/OQ support. The PODs’ flexibility allows them to support multiple products, and they can be easily repurposed. In addition, the cost of 'building' a facility is drastically reduced, as is build time, which increases the return on investment.
“G-CON’s prefabricated cleanroom units feature a complete, yet compressed footprint for Pall’s continuous bioprocessing and viral vector production designs. The implementation of the Pall processes into our POD infrastructure creates an ideal turnkey solution for our customers. These solutions will be readily deployable and scalable, as they reduce the typical design, verification and qualification efforts by standardizing processes and cleanroom environments,” said Maik Jornitz, President and CEO of G-CON Manufacturing. “We are looking forward to combining our PODs with Pall’s process knowledge and designs to serve our joint customer base. The industry requires optimized, fast, scalable solutions, and these requirements will be met through this collaboration.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance